<DOC>
	<DOCNO>NCT02074449</DOCNO>
	<brief_summary>Patients pulmonary arterial hypertension ( PAH ) much high risk death RV ( right ventricle ) weak . The purpose study get good understanding factor determine RV adaptation RV compensate therapy . The investigator also interested Remodulin ( treprostinil ) infuse short period ( approximately 48-72 hour ) affect patient 's quality life , medical care , personal health behavior . Treprostinil , also know Remodulin , approve US Food Drug Administration use treatment PAH . The investigator treat patient Remodulin rapid infusion ( 48 hour ) 6 year . The investigator would like establish practice safe effective benefit center treat PAH .</brief_summary>
	<brief_title>Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil ( Remodulin )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Patients clinically suspect World Health Organization ( WHO ) group I PAH Patients New York Heart Association/WHO functional class IIIV Patients mean pulmonary artery pressure &gt; 25 mmHg , pulmonary capillary wedge pressure &lt; /=15 mmHg , pulmonary vascular resistance &gt; 3 wood unit Age &gt; 18 &lt; 80 No evidence active ischemic heart disease Left ventricular ejection fraction &lt; 50 % Patients significant restrictive lung disease ( FVC &lt; 60 % predict ) and/or significant obstructive lung disease ( FEV1 &lt; 55 % predict ) within 1 year enrollment pulmonary function test available Patients significant , investigatordetermined parenchymal lung disease chest xray CT chest History pulmonary embolism within last three month chronic pulmonary embolism Poorly interpretable grey scale echocardiographic image Contraindications right heart catheterization Moderatesevere aortic mitral valve abnormality Active previous use pulmonary vasoactive medication within previous 12 week Renal failure serum creatinine clearance &lt; 30 ml/hr Highprobability ventilationperfusion scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Right Ventricular Performance</keyword>
	<keyword>Treprostinil</keyword>
	<keyword>Remodulin</keyword>
</DOC>